Zobrazeno 1 - 10
of 1 068
pro vyhledávání: '"Johann, S De Bono"'
Autor:
Ken Herrmann, Andrei Gafita, Johann S. de Bono, Oliver Sartor, Kim N. Chi, Bernd J. Krause, Kambiz Rahbar, Scott T. Tagawa, Johannes Czernin, Ghassan El-Haddad, Connie C. Wong, Zhaojie Zhang, Celine Wilke, Osvaldo Mirante, Michael J. Morris, Karim Fizazi
Publikováno v:
EClinicalMedicine, Vol 77, Iss , Pp 102862- (2024)
Summary: Background: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains
Externí odkaz:
https://doaj.org/article/b900010b053c4d47a08e83b23c5b2523
Autor:
Ricardo Donners, Ines Figueiredo, Daniel Westaby, Dow-Mu Koh, Nina Tunariu, Suzanne Carreira, Johann S. de Bono, Nicos Fotiadis
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study’s objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate target lesion s
Externí odkaz:
https://doaj.org/article/76c557085ee14e639a41f169264874dd
Autor:
Gloria Cecilia Galvan, Nadine A. Friedrich, Sanjay Das, James P. Daniels, Sara Pollan, Shweta Dambal, Ryusuke Suzuki, Sergio E. Sanders, Sungyong You, Hisashi Tanaka, Yeon-Joo Lee, Wei Yuan, Johann S. de Bono, Irina Vasilevskaya, Karen E. Knudsen, Michael R. Freeman, Stephen J. Freedland
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionWe previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in PCs. We observed that restoring
Externí odkaz:
https://doaj.org/article/ec60d6dd2eac4bd18a56190427b615e9
Autor:
Beth Adamson, Nicholas Brittain, Laura Walker, Ruaridh Duncan, Sara Luzzi, Pasquale Rescigno, Graham Smith, Suzanne McGill, Richard J.S. Burchmore, Elaine Willmore, Ian Hickson, Craig N. Robson, Denisa Bogdan, Juan M. Jimenez-Vacas, Alec Paschalis, Jonathan Welti, Wei Yuan, Stuart R. McCracken, Rakesh Heer, Adam Sharp, Johann S. de Bono, Luke Gaughan
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to fu
Externí odkaz:
https://doaj.org/article/a880219dc98f4a75b656758c629cdcd9
Autor:
Amarnath Challapalli, Tara D. Barwick, Suraiya R. Dubash, Marianna Inglese, Matthew Grech-Sollars, Kasia Kozlowski, Henry Tam, Neva H. Patel, Mathias Winkler, Penny Flohr, Azeem Saleem, Amit Bahl, Alison Falconer, Johann S. De Bono, Eric O. Aboagye, Stephen Mangar
Publikováno v:
Molecules, Vol 28, Iss 24, p 8018 (2023)
Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing use of late-imagin
Externí odkaz:
https://doaj.org/article/74674289d27f44588c3184f2bea4b18b
Autor:
Crescens Tiu, Rajiv Shinde, Abhijit Pal, Andrea Biondo, Alex Lee, Nina Tunariu, Shaman Jhanji, Vimal Grover, Kate Tatham, Pascale Gruber, Udai Banerji, Johann S. De Bono, Emma Nicholson, Anna R. Minchom, Juanita S. Lopez
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 189-195 (2021)
Introduction: Immune checkpoint inhibitors (ICIs) are increasingly a standard of care for many cancers; these agents can result in immune-related adverse events (irAEs) including fever, which is common but can rarely be associated with systemic immun
Externí odkaz:
https://doaj.org/article/795643acaadb42b992e7de8af283b261
Autor:
Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S. de Bono
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background and purpose: Chemotherapy-induced neutropenia and neutrophil-to-lymphocyte ratio (NLR) are potentially useful prognostic markers in patients with metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis investigated
Externí odkaz:
https://doaj.org/article/64e2736141b249ca9f83a58bb38e988a
Autor:
Priyanka H. Patel, Nina Tunariu, Daniel S. Levine, Johann S. de Bono, Rosalind A. Eeles, Vincent Khoo, Julia Murray, Christopher C. Parker, Angela Pathmanathan, Alison Reid, Nicholas van As, Alison C. Tree
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AimsOligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen
Externí odkaz:
https://doaj.org/article/9955948fb2c244e5bfa114104c28b317
Autor:
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly
Publikováno v:
Journal of Clinical Oncology. 41:2736-2746
PURPOSE We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally validate this model in a br
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100218- (2021)
Externí odkaz:
https://doaj.org/article/1c7210478d224aa39da90c415bc6c6fd